RT Journal Article
SR Electronic
T1 Selection of long COVID symptoms influences prevalence estimates in a prospective cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.09.22282120
DO 10.1101/2022.11.09.22282120
A1 Wynberg, Elke
A1 de Bree, Godelieve J.
A1 Leenstra, Tjalling
A1 Verveen, Anouk
A1 van Willigen, Hugo D.G.
A1 de Jong, Menno D.
A1 Prins, Maria
A1 Boyd, Anders
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/11/11/2022.11.09.22282120.abstract
AB Background Studies on long COVID differ in the selection of symptoms used to define the condition. We aimed to assess to what extent symptom selection impacts prevalence estimates of long COVID.Methods In a prospective cohort of patients who experienced mild to critical coronavirus disease 2019 (COVID-19), we used longitudinal data on the presence of 20 different symptoms to evaluate changes in the prevalence of long COVID over time when altering symptom selection.Results Changing symptom selection resulted in wide variation in long COVID prevalence, even within the same study population. Long COVID prevalence at 12 months since illness onset ranged from 39.6% (95%CI=33.4-46.2) when using a limited selection of symptoms to 80.6% (95%CI=74.8-85.4) when considering any reported symptom to be relevant.Conclusions Comparing the occurrence of long COVID is already complex due to heterogeneity in study design and population. Disparate symptom selection may further hamper comparison of long COVID estimates between populations. Harmonised data collection tools could be one means to achieve greater reproducibility and comparability of results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis publication is part of the project RECoVERED with project number 10150062010002 of the research programme Infectieziektebestrijding 3 2019-2023, which is financed by the Netherlands Organisation for Health Research and Development (ZonMw) and awarded to M.D. de Jong. This work was additionally supported by the Public Health Service of Amsterdam (Research & Development grant numbers 21-14 and 22-09), awarded to M. Prins.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:RECoVERED is an observation study that was approved by the medical ethical review board of the Amsterdam University Medical Centres (NL73759.018.20). All participants of the RECoVERED study provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.